Related Experiment Videos

Effects of anti-tal-1 oligodeoxynucleotides in T-ALL cell lines

B Anderegg1, M Horstmann, H Kabisch

  • 1Department of Hematology/Oncology, Children's Hospital, Clinical Center for the University of Hamburg, Germany. anderegg@uke.uni-hamburg.de

Cancer Gene Therapy
|March 1, 1997
PubMed

Insights

Antisense oligodeoxynucleotides (ODNs) targeting the SIL/tal-1 fusion gene significantly reduced proliferation and tal-1 mRNA levels in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The tal-1 gene rearrangement is a key factor in childhood T-cell acute lymphoblastic leukemia (T-ALL).
  • The SIL/tal-1 fusion gene represents the most common aberrant form of tal-1, driving leukemogenesis.

Purpose of the Study:

  • To investigate the therapeutic potential of antisense oligodeoxynucleotides (ODNs) against the SIL/tal-1 fusion gene.
  • To evaluate two distinct antisense ODN strategies targeting the aberrant tal-1 transcription.

Main Methods:

  • Treatment of T-ALL cell lines with two different antisense ODN strategies targeting the SIL/tal-1 fusion or tal-1 sequence.
  • Assessment of antiproliferative effects following single-dose ODN application.
  • Quantification of tal-1 mRNA levels using reverse transcription-polymerase chain reaction (RT-PCR).

Main Results:

  • A single 3 mumol dose of ODN induced a significant antiproliferative effect (25-60%) in T-ALL cell lines with the SIL/tal-1 fusion.
  • Antisense ODN treatment markedly reduced tal-1 mRNA levels, confirmed by RT-PCR.
  • Control cell lines with wild-type tal-1 did not exhibit these antiproliferative or mRNA-downregulating effects.

Conclusions:

  • Antisense ODN therapy targeting the SIL/tal-1 fusion gene demonstrates significant antiproliferative activity in T-ALL.
  • This approach effectively downregulates tal-1 mRNA expression, offering a potential therapeutic strategy for T-ALL.
  • The specificity of the effect was confirmed in cell lines with wild-type tal-1.

Related Concept Videos